Remdesiver inhibits viral RNA polymerase and has a broader therapeutic window as it work against SARS-CoV and MERS-CoV. Primary trials have shown improvement of recovery and decreasing respiratory tract infection at a rate of 68% in a clinical settings. However, there is still a lack of randomized-placebo testing